<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01533597</url>
  </required_header>
  <id_info>
    <org_study_id>Bomnal study</org_study_id>
    <nct_id>NCT01533597</nct_id>
  </id_info>
  <brief_title>The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)</brief_title>
  <official_title>Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soonchunhyang University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate if the combination therapy consisting of
      anticholinergics plus alpha-blockers could be beneficial for women suffering from Overactive
      Bladder (OAB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overactive bladder (OAB) describes the symptom complex of urgency, with or without urge
      incontinence, usually with frequency and nocturia.

      The lower urinary tract is innervated by both the parasympathetic and the sympathetic nervous
      system, that act via muscarinic and adrenergic receptors, respectively.

      Antimuscarinics are mainly used for the treatment of patients with OAB, especially women.
      Other than antimuscarinics, a1-blockers have been shown in several clinical reports to be
      useful in treating DO caused by neurological diseases.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Number of Micturition Episodes Per 24 Hours</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric Change of Urgency Episodes Per 24 Hours</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Score of OABSS</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
    <description>Total Score of OABSS(Overactive Bladder Symptom Score) is the sum of 4 questions, ranging from 0 (best possible outcome) to 15 (worst possible outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score of IPSS</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
    <description>Total Score of IPSS(International Prostate Symptom Score) is the sum of 7 questions, ranging from 0 (best possible outcome) to 35 (worst possible outcome). The 7 symptom questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 for a total of maximum 35 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of PVR</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
    <description>Change from baseline in Post-Void Residual (PVR) volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Qmax</measure>
    <time_frame>at week 24 relative to baseline</time_frame>
    <description>maximal urinary flow rate (Qmax) assessed by uroflowmetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Solifenacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Solifenacin plus Tamsulosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>Solifenacin (5mg, qd, oral)</description>
    <arm_group_label>Solifenacin</arm_group_label>
    <other_name>Vesicare</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin plus Tamsulosin</intervention_name>
    <description>Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
    <arm_group_label>Solifenacin plus Tamsulosin</arm_group_label>
    <other_name>Vesicare</other_name>
    <other_name>Harnal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female aged 20 ≤ and ＜ 70 years

          -  History of OAB symptoms for ≥ 3 months

          -  International Prostate Symptom Score (IPSS) ≥ 8 points at Screening and more than 3 in
             total score and 2 in Q 3 index from OABSS questionnaire

          -  An average of ≥ 8 micturitions per 24 hours and ≥ 1 urgency (defined as a level of 3
             to 5 in a 5 point Urinary Sensation Scale) episode (with or without incontinence) per
             24 hours as documented in a 3-day micturition diary

        Exclusion Criteria:

          -  Uroflowmetry - Q max ≤ 10 mL/sec, or Post Void Residual Volume ≥ 15% of voided urine

          -  Any condition that would contraindicate their usage of anticholinergics or alpha
             blockers

          -  History of lower urinary tract surgery (e.g. incontinence surgery or
             electrostimulation)

          -  History of stress urinary incontinence or urinary retention

          -  History of interstitial cystitis, bladder outlet obstruction or other significant
             genitourinary disorder

          -  Pregnant or nursing women

          -  Current urinary tract infection

          -  Neurological bladder dysfunction

          -  Treatment with drugs that may interfere with CYP3A4 metabolic function

          -  Significant hepatic or renal disease

          -  Any other condition which, in the opinion of the investigator, makes the patient
             unsuitable for inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwang Woo Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2012</study_first_submitted>
  <study_first_submitted_qc>February 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2012</study_first_posted>
  <results_first_submitted>January 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2015</results_first_posted>
  <last_update_submitted>January 24, 2015</last_update_submitted>
  <last_update_submitted_qc>January 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soonchunhyang University Hospital</investigator_affiliation>
    <investigator_full_name>Kwang-Woo Lee, MD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Overactive bladder</keyword>
  <keyword>Solifenacin succinate</keyword>
  <keyword>Tamsulosin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Solifenacin</title>
          <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
        </group>
        <group group_id="P2">
          <title>Solifenacin Plus Tamsulosin</title>
          <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Solifenacin</title>
          <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
        </group>
        <group group_id="B2">
          <title>Solifenacin Plus Tamsulosin</title>
          <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.1" spread="8.2"/>
                    <measurement group_id="B2" value="52.3" spread="13.8"/>
                    <measurement group_id="B3" value="52.2" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Number of Micturition Episodes Per 24 Hours</title>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Number of Micturition Episodes Per 24 Hours</title>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.5" upper_limit="-1.2"/>
                    <measurement group_id="O2" value="-2.2" lower_limit="-3.0" upper_limit="-1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numeric Change of Urgency Episodes Per 24 Hours</title>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Numeric Change of Urgency Episodes Per 24 Hours</title>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-3.6" upper_limit="-1.2"/>
                    <measurement group_id="O2" value="-2.1" lower_limit="-2.7" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Score of OABSS</title>
        <description>Total Score of OABSS(Overactive Bladder Symptom Score) is the sum of 4 questions, ranging from 0 (best possible outcome) to 15 (worst possible outcome)</description>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Score of OABSS</title>
          <description>Total Score of OABSS(Overactive Bladder Symptom Score) is the sum of 4 questions, ranging from 0 (best possible outcome) to 15 (worst possible outcome)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" lower_limit="-4.2" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-4.3" upper_limit="-2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Score of IPSS</title>
        <description>Total Score of IPSS(International Prostate Symptom Score) is the sum of 7 questions, ranging from 0 (best possible outcome) to 35 (worst possible outcome). The 7 symptom questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 for a total of maximum 35 points.</description>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Score of IPSS</title>
          <description>Total Score of IPSS(International Prostate Symptom Score) is the sum of 7 questions, ranging from 0 (best possible outcome) to 35 (worst possible outcome). The 7 symptom questions include feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia, each referring to during the last month, and each involving assignment of a score from 0 to 5 for a total of maximum 35 points.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" lower_limit="-10.4" upper_limit="-5.1"/>
                    <measurement group_id="O2" value="-8.3" lower_limit="-10.3" upper_limit="-6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of PVR</title>
        <description>Change from baseline in Post-Void Residual (PVR) volume</description>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Change of PVR</title>
          <description>Change from baseline in Post-Void Residual (PVR) volume</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="8.7" upper_limit="17.6"/>
                    <measurement group_id="O2" value="10.8" lower_limit="6.9" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Qmax</title>
        <description>maximal urinary flow rate (Qmax) assessed by uroflowmetry</description>
        <time_frame>at week 24 relative to baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solifenacin</title>
            <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
          </group>
          <group group_id="O2">
            <title>Solifenacin Plus Tamsulosin</title>
            <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Qmax</title>
          <description>maximal urinary flow rate (Qmax) assessed by uroflowmetry</description>
          <units>mL/sec</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-0.6" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.1" lower_limit="-0.5" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Solifenacin</title>
          <description>Solifenacin: Solifenacin (5mg, qd, oral)</description>
        </group>
        <group group_id="E2">
          <title>Solifenacin Plus Tamsulosin</title>
          <description>Solifenacin plus Tamsulosin: Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small study population</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kwang-Woo Lee</name_or_title>
      <organization>Soonchunhyang Bucheon Hospital</organization>
      <phone>+82 32 621 5465</phone>
      <email>urolkw@schmc.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

